A bone marrow factor contributes to kidney disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.International journal of molecular sciences · 2022
   Review
2. The Combination of Scutellaria baicalensis Georgi andFrontiers in pharmacology · 2020
   Article
3. Sympathetic Activation in Hypertensive Chronic Kidney Disease - A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?Frontiers in physiology · 2019
   Review
4. suPAR as a marker of infection in acute kidney injury - a prospective observational study.BMC nephrology · 2018
   Observational
5. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.Nature reviews. Nephrology · 2018
   Review

Corrections and comments

• Comment on
  Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as